BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21365628)

  • 1. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online.
    Gill S; Loprinzi C; Kennecke H; Grothey A; Nelson G; Woods R; Speers C; Alberts SR; Bardia A; O'Connell MJ; Sargent DJ
    Cancer; 2011 Sep; 117(18):4155-65. PubMed ID: 21365628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators.
    Bardia A; Loprinzi C; Grothey A; Nelson G; Alberts S; Menon S; Thome S; Gill S; Sargent D
    Semin Oncol; 2010 Feb; 37(1):39-46. PubMed ID: 20172363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.
    Renfro LA; Grothey A; Xue Y; Saltz LB; André T; Twelves C; Labianca R; Allegra CJ; Alberts SR; Loprinzi CL; Yothers G; Sargent DJ;
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25359867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.
    Buhl IK; Gerster S; Delorenzi M; Jensen T; Jensen PB; Bosman F; Tejpar S; Roth A; Brunner N; Hansen A; Knudsen S
    PLoS One; 2016; 11(5):e0155123. PubMed ID: 27171152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
    Alwers E; Jansen L; Bläker H; Kloor M; Tagscherer KE; Roth W; Boakye D; Herpel E; Grüllich C; Chang-Claude J; Brenner H; Hoffmeister M
    Mol Oncol; 2020 Feb; 14(2):363-372. PubMed ID: 31816156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy for stage III colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.
    Figueredo A; Fine S; Maroun J; Walker-Dilks C; Wong S
    Cancer Prev Control; 1997 Oct; 1(4):304-19. PubMed ID: 9765754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
    O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
    J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.
    Iwashyna TJ; Lamont EB
    J Clin Oncol; 2002 Oct; 20(19):3992-8. PubMed ID: 12351596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
    Kornmann M; Staib L; Wiegel T; Kron M; Henne-Bruns D; Link KH; Formentini A;
    Clin Colorectal Cancer; 2013 Mar; 12(1):54-61. PubMed ID: 23107590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
    Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of adjuvant systemic chemotherapy for colon cancer.
    Andre T; de Gramont A;
    Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S22-8. PubMed ID: 15212702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.
    de Vos tot Nederveen Cappel WH; Meulenbeld HJ; Kleibeuker JH; Nagengast FM; Menko FH; Griffioen G; Cats A; Morreau H; Gelderblom H; Vasen HF
    Int J Cancer; 2004 Apr; 109(3):468-71. PubMed ID: 14961589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
    Wilkinson NW; Yothers G; Lopa S; Costantino JP; Petrelli NJ; Wolmark N
    Ann Surg Oncol; 2010 Apr; 17(4):959-66. PubMed ID: 20082144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
    Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
    Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
    PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.